Redox Biology (Oct 2020)

A functionally defined high-density NRF2 interactome reveals new conditional regulators of ARE transactivation

  • Jonathan Poh,
  • Amy H. Ponsford,
  • James Boyd,
  • Jonathan Woodsmith,
  • Ulrich Stelzl,
  • Erich Wanker,
  • Nicholas Harper,
  • David MacEwan,
  • Christopher M. Sanderson

Journal volume & issue
Vol. 37
p. 101686

Abstract

Read online

NRF2 (NFE2L2) is a cytoprotective transcription factor associated with >60 human diseases, adverse drug reactions and therapeutic resistance. To provide insight into the complex regulation of NRF2 responses, 1962 predicted NRF2-partner interactions were systematically tested to generate an experimentally defined high-density human NRF2 interactome. Verification and conditional stratification of 46 new NRF2 partners was achieved by co-immunoprecipitation and the novel integration of quantitative data from dual luminescence-based co-immunoprecipitation (DULIP) assays and live-cell fluorescence cross-correlation spectroscopy (FCCS). The functional impact of new partners was then assessed in genetically edited loss-of-function (NRF2−/−) and disease-related gain-of-function (NRF2T80K and KEAP1−/−) cell-lines. Of the new partners investigated >77% (17/22) modified NRF2 responses, including partners that only exhibited effects under disease-related conditions. This experimentally defined binary NRF2 interactome provides a new vision of the complex molecular networks that govern the modulation and consequence of NRF2 activity in health and disease.

Keywords